And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our signal to daydream about weekend plans. Our agenda is rather modest. We hope to spend time with a couple of our short people, engage the official mascots, and catch up on our reading. And what about you? Summer is nearing an end, so perhaps you can take one last jaunt to the ocean or lake. You could also prepare for autumn and purchase a sweater or rake. Or you could check to see if anyone has written any anonymous missives about you. Well, whatever you do, have a grand time. But be safe. By the way, we will be gone until Wednesday while we observe ancient traditions. A colleague will forward the newsletter to you in our absence. Meanwhile, enjoy …
Trump administration restrictions on hiring those who have lived outside of the U.S. is making it difficult for the Food and Drug Administration to attract top talent, STAT writes. The policy “definitely has created an additional challenge, I think, for us. The U.S. just doesn’t graduate the number that we need to fill our vacancies,” says Melanie Keller, acting associate commissioner for scientific and clinical recruitment. The agency must restrict the number of offers of employment they make to people who have lived outside the U.S. for three of the past five years.
About the Author Reprints
Unless this patent was filed simultaneously with the one for Oxycontin, I find the ‘moral outrage’ pedantic at best. “The idea Sackler “could get richer” from the patent was “very disturbing,” says Andrew Kolodny…”
Next some will say it’s disturbing for the head of HHS to have worked for Lilly for many years … oh, wait!